The issue I have is that they're progressing a multitude of assets (it is nice to have lots of options) whereas I wonder if it would be more productive to focus on the most compelling - make these your lead assets and try to get them "over the clinical line" and revenue generating via licence deals etc. I do wonder if they are juggling too much? Be interested in others' thoughts.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-11
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
